Project Grant SB1DK143853
Award Date 9/2/25
Completion Date 8/31/27
Dollars Obligated $571K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $1,192,362 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Averto Medical Inc., a medical device manufacturer in Fremont, California. The grant supports a safety and efficacy clinical trial of Averto's COLOSEAL ICD System, a minimally invasive medical device designed as an alternative to temporary ostomies for the surgical treatment of...
- This Project Grant award of $964,718.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The funding supports the "VESOPHAGUS - PREDICTING SURGICAL OUTCOMES USING A VIRTUAL ESOPHAGUS" project at Northwestern University, which aims to utilize a virtual esophagus simulation model (VESOPHAGUS) to improve the clinical evaluation and management of...
- This federal Project Grant award of $1,222,594.00, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research investigating the role of glutathione peroxidase 3 (GPX3) in regulating esophageal epithelial remodeling, subepithelial fibrosis, and eosinophil recruitment in eosinophilic esophagitis (EoE). The research, led by the primary awardee Vanderbilt...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), through the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded a $324,678 Project Grant to Lumina Medical LLC, located in California, to develop an innovative Motorized Girth Adjustable Dilator. This medical device is designed to improve patient adherence to static-passive stretching treatment for anorectal disorders such as anismus and anal stenosis, which collectively affect...
- This federal Project Grant award was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The $306,867 award to Dupage Medical Technology Inc. supports the development of a new drug to treat ischemia-reperfusion injury associated with kidney transplantation. The project aims to develop a therapy that can reduce inflammation and thrombosis without causing excessive...
- This Project Grant award of $325,408 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) supports the development of an easy-to-operate endoscopic automatic gastroplasty device that mimics the effect of gastric bypass/bariatric surgery. The device is intended to provide a minimally invasive, non-surgical weight loss solution for the treatment of diabetes and obesity. The technology creates a reinforced circular plication of stomach tissue to reduce the stomach...
- The federal Project Grant award of $287,250 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award was granted to Persista Bio Inc. to develop the manufacturing process for the cell capsule of the company's O2Line implant system, an advanced oxygenated cell encapsulation system targeting the treatment of type 1 diabetes (T1D). The key products to be...
- This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $226,192 to Endonavis LLC to develop a novel over-the-scope platform for controlling variceal bleeding. The project aims to mate Endonavis' single-use endoscope technology with a novel balloon design to enable endoscopic visualization and active monitoring during placement for improved...
- This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $808,866 to Progenra Inc., a biotechnology firm located in Malvern, Pennsylvania. The funding supports research to evaluate novel small molecule compounds that activate the ubiquitin proteasome system (UPS) as potential therapeutics for treating acute and chronic pancreatitis. Key objectives include assessing...
- The National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases awarded $3.6 million under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Anagram Therapeutics Inc. to develop a novel pancreatic enzyme replacement therapy. Specifically, Anagram will engineer lipase enzymes for improved stability against low pH and proteolytic degradation. This will allow for effective digestion of fats in both the stomach and small...